Skip to content

Efficacy and safety of propofol combined with esketamine for therapeutic enteroscopy sedation

Efficacy and safety of propofol combined with esketamine for therapeutic enteroscopy sedation

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069014
Enrollment
Unknown
Registered
2023-03-03
Start date
2021-11-30
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endoscopic therapy

Interventions

Fentanyl combined with propofol (Group F):the main anesthesia drugs are fentanyl and propofol
Esketamine combined with propofol (Group E):the main anesthesia drugs are esketamine and propofol

Sponsors

Zhongshan Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: ? Older than 18 years old ? Endoscopic therapy under colonoscopy is planned ? ASA class I-III ? Sign informed consen

Exclusion criteria

Exclusion criteria: ? Allergy to known narcotic drugs ? Uncontrolled hypertension or hypertensive crisis ? Ischemic heart disease ? Mental illness ? Taking analgesics for a long time due to chronic pain ? Pregnant or lactating women ? Drug abuse ? Epilepsy ? Intracranial hypertension

Design outcomes

Primary

MeasureTime frame
Total propofol dosage in each group;

Secondary

MeasureTime frame
Blood pressure change;oxygen saturation;Heart rate;Respiration rate;Incidence of sedatin-related adverse events;Utilization rate of vasoactive drugs;Onset of effective;Awake time;Satisfaction of the operator with anesthesia;Satisfaction of the patient with anesthesia;Occurrence of postoperative adverse events;The occurrence of a postoperative undesirable mental state;

Countries

China

Contacts

Public ContactYao Minmin
yao.minmin@zs-hospital.sh.cn18516593218

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026